SungJun Park

Mr. SungJun Park

National Heart Lung and Blood Institute, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Science
Verified
Journal Article
Closed access
JKJeonghan Kim
Jeonghan Kim
RGRajeev Gupta
Rajeev Gupta
LBLuz P. Blanco
Luz P. Blanco
SYShutong Yang
Shutong Yang
ASAnna Shteinfer-Kuzmine
Anna Shteinfer-Kuzmine
JCJay H. Chung
Jay H. Chung
VDACs are MOM's ruin: Mitochondrial DNA (mtDNA) is normally kept within the mitochondria. It can be released into the cytosol in response to stress and thus encounter cytosolic DNA sensors, triggering type I interferon responses. During apoptosis, mtDNA release is mediated by macropores in the mitochondrial outer membrane (MOM) created by oligomerization of the proteins BAX and BAK. Kim et al. found that during oxidative stress, mtDNA escapes instead through macropores formed by oligomerization of voltage-dependent anion channels (VDACs) (see the Perspective by Crow). In a mouse model of lupus, an inhibitor of VDAC oligomerization diminished mtDNA release and downstream signaling events. This treatment reduced lupus-like symptoms in the model, suggesting a potential therapeutic route for conditions mediated by mtDNA release. Science , this issue p. 1531 ; see also p. 1445

Verified
Journal Article
Open access
PDF file
ASAndrew Jacob Herse Sedlack
Andrew Jacob Herse Sedlack
JKJay Knutson
Jay Knutson
KLKatie A. Link
Katie A. Link
ABAlexandra Brown
Alexandra Brown
JKJeonghan Kim
Jeonghan Kim
JKJay Knutson
Jay Knutson
Computational modeling can provide a mechanistic and quantitative framework for describing intracellular spatial heterogeneity of solutes such as oxygen partial pressure (pO2). This study develops and evaluates a finite-element model of oxygen-consuming mitochondrial bioenergetics using the COMSOL Multiphysics program. The model derives steady-state oxygen (O2) distributions from Fickian diffusion and Michaelis–Menten consumption kinetics in the mitochondria and cytoplasm. Intrinsic model parameters such as diffusivity and maximum consumption rate were estimated from previously published values for isolated and intact mitochondria. The model was compared with experimental data collected for the intracellular and mitochondrial pO2 levels in human cervical cancer cells (HeLa) in different respiratory states and under different levels of imposed pO2. Experimental pO2 gradients were measured using lifetime imaging of a Förster resonance energy transfer (FRET)-based O2 sensor, Myoglobin-mCherry, which offers in situ real-time and noninvasive measurements of subcellular pO2 in living cells. On the basis of these results, the model qualitatively predicted (1) the integrated experimental data from mitochondria under diverse experimental conditions, and (2) the impact of changes in one or more mitochondrial processes on overall bioenergetics.

1 December 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
IMIjeoma M. Muo
Ijeoma M. Muo
SPSungJun Park
SungJun Park
ASAntoine Smith
Antoine Smith
DSDanielle A. Springer
Danielle A. Springer
MAMichele D. Allen
Michele D. Allen
JCJay H. Chung
Jay H. Chung

17 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSungJun Park
SungJun Park
FAFaiyaz Ahmad
Faiyaz Ahmad
RBRobert J. Bahde
Robert J. Bahde
APAndrew Philp
Andrew Philp
JKJeonghan Kim
Jeonghan Kim
JCJay H. Chung
Jay H. Chung
AMP-activated protein kinase (AMPK) is an evolutionarily conserved energy sensor. Activation of AMPK leads to a number of metabolic benefits, including improved mitochondrial function in skeletal muscle and lowering of serum glucose levels in type-2 diabetes models. However, direct activation of AMPK leads to cardiac enlargement, and an alternative strategy that activates AMPK without affecting the heart is needed. Inhibition of phosphodiesterase 4 (PDE4), which is poorly expressed in the human heart, activates AMPK in other tissues. In a screen to identify novel PDE4 inhibitors, we discovered compound CBU91, which is 5–10 fold more potent than rolipram, the best characterized PDE4 inhibitor. CBU91, like rolipram, is able to activate AMPK and Sirt1 and increase mitochondrial function in myotubes. These findings suggest that activation of AMPK in myotubes is a general property of PDE4 inhibition and that PDE4 inhibition may activate AMPK in metabolically relevant tissues without affecting the heart.